Objective To investigate the regulatory mechanism of transforming growth factor-β1 (TGF-β1) in different types of mitral valvular disease (MVD) with atrial fibrillation (AF). Methods From August 2011 to August 2012, patients with moderate to severe MVD accompanied by AF who required mitral valve replacement at the Department of Cardiovascular Surgery, West China Hospital, Sichuan University, were included. Based on echocardiographic results, patients were divided into two groups: a mitral regurgitation (MR) with AF (MR-AF) group and a mitral stenosis (MS) with AF (MS-AF) group. Left atrial tissue samples were collected during surgery. Techniques such as enzyme-linked immunosorbent assay, real-time fluorescence quantitative polymerase chain reaction, immunohistochemistry, and Western blotting were used to detect key molecules in the TGF-β1/JNK pathway. Results Sixteen patients were enrolled. There were 8 patients in the MR-AF group, including 5 males and 3 females, with an average age of (41.38±11.19) years; and 8 patients in the MS-AF group, including 6 males and 2 females, with an average age of (43.12±5.30) years. The left atrial volume load was higher in MR-AF patients, while the left atrial pressure load was higher in MS-AF patients. In MS-AF patients, the relative expression levels of MAPK9, JUN, CASP3, BAX, and BCL2 mRNA in left atrial tissues were significantly upregulated. The serum TGF-β1 protein level and the relative expression levels of p-JNK, p-c-Jun, and Caspase-3 proteins in the left atrial tissues of the MR-AF group were higher. Myocardial cell damage was more severe in the MS-AF group, and the protein expression level of Bcl-2 was higher. Conclusion Different MVD have distinct hemodynamic characteristics. The myocardium of the left atrium in MR-AF patients is more prone to apoptosis, possibly through the activation of the TGF-β1/JNK signaling pathway.
Citation：
CHANG Chao, FU Bo, ZHU Xiaolong, ZHANG Chongjie, ZHAO Xia, TANG Hong, XIAO Xijun, BAI Yunpeng. Regulation of TGF-β1/JNK signaling pathway in patients with different types of mitral valve diseases complicated by atrial fibrillation. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2026, 33(2): 291-299. doi: 10.7507/1007-4848.202507006
Copy
Copyright ? the editorial department of Chinese Journal of Clinical Thoracic and Cardiovascular Surgery of West China Medical Publisher. All rights reserved
| 1. |
|
| 2. |
|
| 3. |
|
| 4. |
|
| 5. |
|
| 6. |
|
| 7. |
|
| 8. |
|
| 9. |
|
| 10. |
|
| 11. |
|
| 12. |
|
| 13. |
Babapoor-Farrokhran S, Tarighati Rasekhi R, Gill D, et al. How transforming growth factor contributes to atrial fibrillation? Life Sci, 2021, 266: 118823.
|
| 14. |
|
| 15. |
|
| 16. |
|
| 17. |
|
| 18. |
Frangogiannis NG. Transforming growth factor-β in myocardial disease. Nat Rev Cardiol. 2022, 19(7): 435-455.
|
| 19. |
|
| 20. |
|
| 21. |
|
| 22. |
|
| 23. |
|
| 24. |
|
| 25. |
|
| 26. |
|
| 27. |
|
| 28. |
|
| 29. |
|
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13. Babapoor-Farrokhran S, Tarighati Rasekhi R, Gill D, et al. How transforming growth factor contributes to atrial fibrillation? Life Sci, 2021, 266: 118823.
- 14.
- 15.
- 16.
- 17.
- 18. Frangogiannis NG. Transforming growth factor-β in myocardial disease. Nat Rev Cardiol. 2022, 19(7): 435-455.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.
